Streetbeat News

Regulatory

ARVN

PFE

Levi & Korsinsky has initiated an investigation into Arvinas, Inc. for potential federal securities law violations. Arvinas and Pfizer have delayed the completion of their Phase 3 trial for the breast cancer therapy vepdegestrant, moving the date from November 2024 to January 2025.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

SUI

Levi & Korsinsky has initiated an investigation into Sun Communities, Inc. (NYSE:SUI) for potential violations of federal securities laws following a report by Blue Orca Capital.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

INTC

Intel has been awarded $7.9 billion in federal grants from the Biden administration as part of the CHIPS Act, according to the US Department of Commerce.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

AVXL

Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug blarcamesine to the European Medicines Agency (EMA) for the treatment of Alzheimer's Disease. This marks the first marketing authorization submission for blarcamesine.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

QTRX

Levi & Korsinsky has initiated an investigation into Quanterix Corporation for potential securities fraud. The company disclosed an error in the capitalization of labor and overhead costs affecting inventory valuation since 2021.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

HRMY

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential violations of federal securities laws, following a report by Scorpion Capital raising concerns about their narcolepsy drug, Wakix.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

THTX

Theratechnologies has resubmitted its supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin to the FDA. This resubmission addresses concerns from a previous Complete Response Letter. The F8 formulation aims to replace EGRIFTA SV® with a simplified dosing regimen for treating excess abdominal fat in adults with HIV and lipodystrophy.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

PCRX

Levi & Korsinsky has initiated an investigation into Pacira BioSciences, Inc. for potential violations of federal securities laws. This follows a press release by Pacira on August 9, 2024, regarding a lawsuit outcome against eVenus for patent infringement.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

NGNE

Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential violations of federal securities laws. This follows a press release by Neurogene reporting interim clinical data from a Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

OKLO

Levi & Korsinsky has initiated an investigation into Oklo Inc. for potential securities fraud following a critical short report by Kerrisdale Capital. The report highlights Oklo's lack of regulator-approved designs, revenue, and commercial viability.

Portfolio Pulse from

November 26, 2024 | 12:45 pm